Hyperprolactinemia in systemic lupus erythematosus?

Scandinavian Journal of Rheumatology

Volumn 25, Issue 2, 1996, Pages 97-102

  Ostendorf, B ^a   Fischer, R ^a   Santen, R ^a   Schmitz Linneweber, B ^b   Specker, Ch ^a   Schneider, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Disease activity; Hyperprolactinernia (HPRL); Systemic lupus erythematosus (SLE)

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN A; ESTROGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; THYROID HORMONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0029985229     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749609069215     Document Type: Article

References (47)

1. Smith PE. The effect of hypophysectomy upon the involution of the thymus in rat. Anat Rec 1930; 47: 119-29.
2. Nagy E, Berczi I, Wren GE, Asa SL, Kovaks K. Immunomodulation by bromocriptine. Immunopharmacology 1983; 6: 231-43.
3. Dineen JK, Kelly JD. The suppression of rejection of Nippostrongylus brasiliensis in lactating rats: the nature of immunologic defect. Immunology 1973; 24: 552-8.
4. Russel DH. New aspects of prolactin and immunity: A lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol Sci 1989; 10: 40-4.
5. Berzci I, Nagy E, Asa S, Kovacs K. The influence of pituary hormones on adjuvant arthritis. Arthritis Rheum 1984; 27: 682-7.
6. Riskind PN, Massacesi L, Dolittle TH, Hauser SL. The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol 1991; 29: 542-7.
7. Palestine AG, Nussenblatt RB, Gelato M. Therapy for autoimmune uveitis with low-dose cyclosporin plus bromocriptine. Transplant Proc 1988; 20: 131-5.
8. Ferrari C, Boghen M, Paracchi A. Thyroid autoimmunity in hyperprolactinemic disorders. Acta Endocrinol 1983; 104: 35-41.
9. Lavalle C, Loyo E, Panigua R. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol 1987; 14: 268-72.
10. Folomeev M, Prokaeva T, Nassonova V, Nassonev E, Masenko E, Ovtraht N. Prolactin levels in men with SLE and RA (letter). J Rheumatol 1991; 18: 349-53.
11. Jarae-Quezada L, Graef A, Lavalle C. Prolactin and gonadal hormone during pregnancy in systemic lupus erythematosus. J Rheumatol 1991; 18: 349-53.
12. Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vassey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: Association with disease activity. Am J Med Sci 1992; 303: 222-6.
13. Mc Murray RW, Allen SH, Braun AL, Rodriguez F, Walker SE. Longstanding hyperprolactinemia associated with systemic lupus erythematosus: Possible hormonal stimulation of an autoimmune disease. J Rheumatol 1994; 21: 5, 843-50.
14. Mc Murray RW, Keisler D, Kanuckel K, Izui S, Walker SE. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991; 147: 3780-7.
15. Mc Murray RW, Keisler D, Walker SE. Hyperprolactinemia accelerates disease activity in the male NZB/W mouse model of SLE. Arthritis Rheum 1991; 34: S163 (abstr C 182).
16. Mc Murray RW, Keisler D, Tzui S, Hoffman RW, Walker SE. Postpartum disease activity in the female b/w mouse model of SLE. Arthritis Rheum 1991; 34: S163 (abstr C 183).
17. Berzci I, Nagy E, Asa S, Kovacs K. The influence of pituary hormones on adjuvant arthritis. Arthritis Rheum 1984; 27: 682-7.
18. Neidhart M, Larson DF. Freund's complete adjuvant induces descarboxylase activity in the central nervous system of male rats and triggers the releases of pituary hormones. J Neuroimmunol 1990; 26: 97-105.
19. Weber G, Frey H. Zur Behandlung der Psoriasis arthropatica mit Bromocriptin. Z Hautkr 1986; 61: 1456-66.
20. Buskila D, Sukenik S, Holcberg G, Horowitz J. Improvement of psoriatic arthritis in a patient treated with bromocriptine for hyperprolactinemia. J Rheumatol 1991; 18: 611-2.
21. Hedner LP, Bynke G. Endogenous iridocyclitis relieved during treatment with bromocriptine. Am J Ophthalmol 1985; 100: 618-9.
22. Bravo G, Zazueta B, Lavalle C. An acute remission of Reiter's syndrome in male patients treated with bromocriptine. J Rheumatol 1992; 19: 747-50.
23. Walker SE, Allen SH, Hoffman RW, Mc Murray RW. Review - Prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus 1995, 4: 3-9.
24. Tan EM; Cohen AS, Fries JF; Masi AT, Mc Shane DJ; Rothfield NF; Schaller JG et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
25. Schneider M, Hengst K, Waldendorf B, Högemann B, Gerlach U. The value of serum laminin P1 in monitoring disease activity in patients with systemic lupus erythematosus. Scand J Rheumatology 1988; 17: 417-22.
26. Lavalle C. Prolactin - A hormone with immunoregulatory properties that leads to new therapeutic approaches in rheumatic diseases. J Rheumatol 1992; 19: 6, 839-41.
27. Jara LJ, Lavalle C, Espinoza LR. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J Rheumatol 1992; 19: 9, 1333-6.
28. Espinoza LR. Prolactin. Its potential role in systemic erythematosus (SLE).Lupus (abstr), abstracts from the Fourth International Conference on SLE, 1995; 4 (suppl 2): 66.
29. Jara LJ, Lavalle C, Fraga A, Gomez-Sanchez C, Silveira LH. Prolactin, Immunoregulation and autoimmune diseases. Semin Arthritis Rheum 1991; 20: 5, 273-84.
30. Reber PM. Prolactin and immunomodulation. Am J Med, 1993; 95, 637-44.
31. Pauzner R, Urowitz MB, Gladman D, Gough JM. Prolactin in systemic Lupus erythematosus. J Rheumatol, 1994; 21: 11, 2064-7.
32. Conconi M, Walker AM. Chloroquine affects prolactin secretion and golgi morphology in the mammotroph: Endocrinology 1984; 114: 725-34.
33. Ben-David M, Danon A, Benveniste R. Results of radioimmunoassays of rat pituitary and serum prolactin after adrenalectomy and perphenazine treatment in rats. J Endocrinol, 1972; 50: 559.
34. Stryker TD, Molitch ME. Reversible hyperthyrotropinemia, hyperthyroxinemia and hyperprolactinemia due to adrenal insuffiency. Am J Med 1985; 79: 271.
35. Russell DH, Kiber R, Matrisian L, Larson DF, Poulos B, Magun BE. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporin. J Immunol 1985; 134: 3027-31.
36. Sakata S, Nakamura S, Milura K. Autoantibodies against thyroid hormones or iodothyronine: implications in diagnosis, thyroid function, treatment and pathogenesis. Ann Intern Med 1985; 103: 579-89.
37. Hattori N, Ikekubo K, Ishihara T, Mridera K, Hino M, Kurahachi H. Effects of anti-prolactin autoantibodies on serum prolactin measurements. European Journal of Endocrinology 1994; 130: 434-7.
38. Lindstedt G. Endogenous antibodies against prolactin "new" cause of hyperprolactinemia. European Journal of Endocrinology 1994; 130: 429-32.
39. Gala RR, Shevach EM. Identification by analytical flow cytometry of prolactin receptors on immunocompetent cell populations in the mouse. Endocrinology, 133: 1617-23.
40. Ferrai C, Boghen M, Paracchi A. Thyroid autoimmunity in hyperprolactinemic disorders. Acta Endocrinol 1982; 100: 184-8.
41. Ishibashi M, Yamaji T. Immunological abnormalities with hyperprolactinemia. The Endocrine Society. 71. Annual meeting 1989; (abstr). pp 407.
42. Honbo KS, Herle AJV, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med 1978; 64: 782.
43. Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 1985; 6: 245.
44. Lim VS, Kathpalia SC, Frohman LA. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: Reversal after transplantation. J Clin Endocrinol Metab 1979; 48: 101.
45. Batrinos ML, Panitsa-Faflia C, Tsiganou E, Liapi C. Incidence and characteristics of microprolactinomas (3-5mm) in 4199 women assayed for prolactin. Horm Metab Res 1992; 24: 384-91.
46. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH and the committee on prognosis studies in SLE. Arthritis Rheum 1992; 35: 630-40.
47. Mc Murray RW, Allen SH, Weidensaul D, Walker SE. An open label therapeutic trial of bromocriptine in systemic lupus erythematosus. Lupus 1995; 4 (Suppl 2): p 66.